Article info
PDFStomach
Original research
Loss of ARID1A activates mTOR signaling and SOX9 in gastric adenocarcinoma—rationale for targeting ARID1A deficiency
- Correspondence to Dr Shumei Song, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; ssong{at}mdanderson.org; Dr Jaffer A Ajani, Department of Gastrointestinal Medical Oncology, Unit 426, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Bouulevard, Houston, TX, USA, 77030-4009; jajani{at}mdanderson.org
Citation
Loss of ARID1A activates mTOR signaling and SOX9 in gastric adenocarcinoma—rationale for targeting ARID1A deficiency
Publication history
- Received July 28, 2020
- Revised February 20, 2021
- Accepted March 2, 2021
- First published March 30, 2021.
Online issue publication
February 08, 2022
Article Versions
- Previous version (30 March 2021).
- Previous version (13 April 2021).
- You are viewing the most recent version of this article.
Supplementary Data
This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.
Supplementary Data
This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.